MedTrace Logo

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

NCT07652294 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 645

Last updated 2026-08-18

No results posted yet for this study

Summary

This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study).

Conditions

Interventions

DRUG

SPY001

Experimental

DRUG

SPY002

Experimental

DRUG

SPY003

Experimental

Sponsors & Collaborators

  • Spyre Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • SKYLINE Study Director · Spyre Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-08
Primary Completion
2029-03-02
Completion
2030-01-03
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Georgia
  • Greece
  • Poland
  • Serbia
  • South Korea
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07652294 on ClinicalTrials.gov